

IdentifySensors Has Finalized Proof-of-Concept Research for All-New COVID Testing Method

2022-01-15 Cleveland – IdentifySensors Biologics, along with leading researchers at Purdue University, developed a breakthrough technology that intends to reshape the future of diagnostic testing. It is their innovative nanosensor technology, Check4[™], that won them the 2021 TechOhio Start-Up Creativity Challenge Award.

TechOhio called on its network of startups, small businesses, and tech companies to share their most creative problem-solving solutions. They wanted to learn about new products that helped overcome an issue, new software that solved problems, and technology innovations that created something that never before seemed possible. Check4[™], the disruptive new diagnostic testing platform that intends to be completely different from any others currently on the market, met that criteria. It's a molecular gene test that uses nanosensor technology to detect early and asymptomatic infections.

"With COVID still raging around the globe, our test is a game-changer," said Dr. Gregory Hummer, founder of IdentifySensors Biologics. "It's fast, affordable and intends to provide accurate results withing minutes on your smartphone. Check4[™] can help us get back to living a more normal life."

IdentifySensors is currently in the commercialization stage with Check4^m. It is a testing platform containing two parts – a re-useable reader and cartridges that intend to check for several infections and pathogens. The first cartridges are intended to test for COVID and the multiple variants, and then a multiplex cartridge which will test for COVID and influenza A and B.

Check4[™] is easy to use and fast, accurate, and affordable. Using saliva and the user's smartphone, results will be delivered within minutes. Future intended tests include MRSA, Lyme, Hep C and B, foodborne pathogens, and more.

×

Pathogen detection sensor reader in hand.

Read the <u>original article</u> on IdentifySensors.